Unicycive Therapeutics, Inc. Cash Flow Statement
UNCY|3 years of annual SEC 10-K data (FY2022-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Unicycive Therapeutics, Inc. used $18M in operating cash flow and negative free cash flow of $18M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Net Income | -$30.5M | -$18.1M | -$10.0M |
| Depreciation & Amortization | $9.0K | $7.0K | $468.0K |
| Operating Cash Flow | -$18.3M | -$15.7M | -$5.8M |
| Capital Expenditures | $12.0K | $2.0K | $29.0K |
| Free Cash Flow | -$18.3M | -$15.7M | -$5.8M |
| Dividends Paid | $1.1M | $900.0K | - |
| FCF Margin | -2710.4% | -1645.9% | -609.5% |